Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) open the trading on Thursday, with great promise as it jumped 3.48% to $0.61, before settling in for the price of $0.59 at the close. Taking a more long-term approach, ADAP posted a 52-week range of $0.53-$2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 193.13%. Meanwhile, its Annual Earning per share during the time was 10.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 71.06%. This publicly-traded company’s shares outstanding now amounts to $255.70 million, simultaneously with a float of $226.47 million. The organization now has a market capitalization sitting at $155.40 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6170, while the 200-day Moving Average is $0.9221.
Adaptimmune Therapeutics Plc ADR (ADAP) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Adaptimmune Therapeutics Plc ADR’s current insider ownership accounts for 11.49%, in contrast to 40.06% institutional ownership. According to the most recent insider trade that took place on Jan 17 ’25, this organization’s Chief Medical Officer sold 5,584 shares at the rate of 0.58, making the entire transaction reach 3,243 in total value, affecting insider ownership by 7,510. Preceding that transaction, on Jan 17 ’25, Company’s Chief Patient Supply Officer sold 5,584 for 0.58, making the whole transaction’s value amount to 3,243. This particular insider is now the holder of 7,510 in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Adaptimmune Therapeutics Plc ADR’s EPS increase for this current 12-month fiscal period is 71.06% and is forecasted to reach -0.08 in the upcoming year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Let’s observe the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). It’s Quick Ratio in the last reported quarter now stands at 3.82. The Stock has managed to achieve an average true range (ATR) of 0.04. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.88.
In the same vein, ADAP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.21, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be -0.08 at the market close of one year from today.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
[Adaptimmune Therapeutics Plc ADR, ADAP] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 54.77% While, its Average True Range was 0.0390.
Raw Stochastic average of Adaptimmune Therapeutics Plc ADR (ADAP) in the period of the previous 100 days is set at 11.95%, which indicates a major fall in contrast to 84.61% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 37.57% that was lower than 72.12% volatility it exhibited in the past 100-days period.
